Talat Imran Biography and Net Worth

CEO of Rani Therapeutics

Talat was appointed CEO in June 2021. Talat has been a key member of Rani's executive team, most recently serving as the company's Vice President, Strategy since 2014. In addition to his role at Rani, Talat has been a venture capitalist with several healthcare-focused Silicon Valley funds, including InCube Ventures, LP, and VentureHealth. Previously, he also served as Chief Executive Officer of Venture Web Partners, a web application development firm. He earned a B.A. in Computer Science from the University of California, Santa Cruz.

What is Talat Imran's net worth?: The estimated net worth of Talat Imran is at least $395.75 thousand as of July 17th, 2026. Mr. Imran owns 469,736 shares of Rani Therapeutics stock worth more than $395,753 as of August 28th. This net worth evaluation does not reflect any other assets that Mr. Imran may own. Learn More about Talat Imran's net worth.
How do I contact Talat Imran?: The corporate mailing address for Mr. Imran and other Rani Therapeutics executives is , , . Rani Therapeutics can also be reached via phone at 408-457-3700 and via email at [email protected]. Learn More on Talat Imran's contact information.
Has Talat Imran been buying or selling shares of Rani Therapeutics?: During the past quarter, Talat Imran has bought $25,200.00 of Rani Therapeutics stock. Most recently, on Friday, July 17th, Talat Imran bought 35,000 shares of Rani Therapeutics stock. The stock was acquired at an average cost of $0.72 per share, with a total value of $25,200.00. Following the completion of the transaction, the chief executive officer now directly owns 469,736 shares of the company's stock, valued at $338,209.92. Learn More on Talat Imran's trading history.
Who are Rani Therapeutics' active insiders?: Rani Therapeutics' insider roster includes Mir Imran (Director), Talat Imran (CEO), Alireza Javadi (Chief Technical Officer), and Kate McKinley (Chief Business Officer). Learn More on Rani Therapeutics' active insiders.
Are insiders buying or selling shares of Rani Therapeutics?: In the last year, Rani Therapeutics insiders bought shares 3 times. They purchased a total of 2,154,334 shares worth more than $1,300,040.40. In the last year, insiders at the sold shares 3 times. They sold a total of 5,923,386 shares worth more than $15,714,731.08. The most recent insider tranaction occured on July, 21st when Director Mir A Imran bought 36,000 shares worth more than $24,840.00. Insiders at Rani Therapeutics own 26.7% of the company. Learn More about insider trades at Rani Therapeutics.
Information on this page was last updated on 7/21/2026.

Talat Imran Insider Trading History at Rani Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/17/2026	Buy	35,000	$0.72	$25,200.00	469,736
12/27/2024	Sell	8,014	$1.41	$11,299.74	486,737
12/9/2024	Buy	10,296	$1.94	$19,974.24	494,751
12/6/2023	Buy	10,000	$2.27	$22,700.00	484,455
12/4/2023	Buy	5,000	$2.57	$12,850.00	474,455
11/29/2023	Buy	20,000	$2.05	$41,000.00	469,455

Talat Imran Buying and Selling Activity at Rani Therapeutics

Rani Therapeutics Company Overview

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Today's Range

Now: $0.84

$0.84

$0.86

50 Day Range

MA: $0.78

$0.63

$0.92

2 Week Range

Now: $0.84

$0.44

$3.87

Volume

260,627 shs

Average Volume

996,590 shs

Market Capitalization

$117.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78